Tech Company Financing Transactions
NK IO Funding Round
NK IO, based in London, England, secured $1.6 million from Imperial College Innovation Fund, Meltwind Advisory and Start Codon.
Transaction Overview
Company Name
Announced On
7/25/2023
Transaction Type
Venture Equity
Amount
$1,550,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to drive its cell therapy candidates through full pre-clinical testing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Care Of Taylor Vinters, 25 Old Broad Street 33rd Floor, Towe
London, England, EC2N 1HQ
UK
London, England, EC2N 1HQ
UK
Phone
Undisclosed
Website
Email Address
Overview
NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Thompson
Chief Operating Officer
Andrew Baxendale
Co-Founder
Hugh Brady
Browse more venture capital transactions:
Prev: 7/25/2023: Nuqleous venture capital transaction
Next: 7/25/2023: Akooda venture capital transaction
Share this article
News on VC Transactions
We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs